
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quince Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

22053A107

(CUSIP Number)

12/31/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-
-

SCHEDULE 13G

CUSIP No. 22053A107

Names of Reporting Persons

1

Sofinnova Capital VIII

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

FRANCE

Number of Shares 5 Sole Voting Power

Beneficially Owned by Each Reporting Person With: 2,397,711.00
 Shared Voting Power
 6
 0.00
 Sole Dispositive Power
 7
 2,397,711.00
 Shared Dispositive Power
 8
 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9
 2,397,711.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

 Percent of class represented by amount in row (9)

11
 5.4 %

12
 Type of Reporting Person (See Instructions)
 OO

Comment for Type of Reporting Person: Note to Items 5 and 6: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Capital VIII ("SC VIII"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Henrijetta Richter ("Richter"), Maina Bhama ("Bhama"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou") and Karl Naegler ("Naegler") the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, Richter, Bhama, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares.

SCHEDULE 13G

CUSIP No. 22053A107

1
 Names of Reporting Persons
 Sofinnova Partners SAS, a French corporation
 Check the appropriate box if a member of a Group (see instructions)

2
 (a)
 (b)

3
 Sec Use Only
 Citizenship or Place of Organization

4
 FRANCE
 Sole Voting Power
 5

Number of Shares Beneficially Owned by Each Reporting Person With: 2,397,711.00
 Shared Voting Power
 6
 0.00
 Sole Dispositive Power
 7
 2,397,711.00
 Shared Dispositive Power
 8
 0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
 2,397,711.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 5.4 %

Type of Reporting Person (See Instructions)

12 OO

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

Names of Reporting Persons

1 Antoine Papiernik
 Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 FRANCE

Sole Voting Power

5 2,397,711.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power
 0.00

7 Sole Dispositive Power
 2,397,711.00

8 Shared Dispositive Power
 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 2,397,711.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 5.4 %

Type of Reporting Person (See Instructions)

12 IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

1	Names of Reporting Persons
	Henrijette Richter
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DENMARK
	Sole Voting Power
5	2,397,711.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	2,397,711.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	2,397,711.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	5.4 %
12	Type of Reporting Person (See Instructions)
	IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Richter, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Richter, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

Names of Reporting Persons

1

Maina Bhaman

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED KINGDOM

Sole Voting Power

5

2,397,711.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

6 Shared Voting Power

6

0.00

7 Sole Dispositive Power

7

2,397,711.00

8 Shared Dispositive

8

Power
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,397,711.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

5.4 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Bhaman, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Bhaman, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

Names of Reporting Persons

1

Graziano Seghezzi

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

ITALY

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power
 2,397,711.00
 Shared Voting Power
 6
 0.00
 Sole Dispositive Power
 7
 2,397,711.00
 Shared Dispositive Power
 8
 0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

2,397,711.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 5.4 %

Type of Reporting Person (See Instructions)

12 IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Seghezzi, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Seghezzi, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

1 Names of Reporting Persons

Anta Gkelou

Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 GREECE

Sole Voting Power
 5

2,397,711.00

Number of Shares Beneficially Owned by Each Reporting Person With: 6 Shared Voting Power

0.00

Sole Dispositive Power
 7

2,397,711.00

Shared Dispositive Power
 8

0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
 2,397,711.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 5.4 %

Type of Reporting Person (See Instructions)

12 IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Gkelou, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Gkelou, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

CUSIP No. 22053A107

Names of Reporting Persons

1 Karl Naegler
 Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 GERMANY

Sole Voting Power

5 2,397,711.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power
 0.00

7 Sole Dispositive Power
 2,397,711.00

8 Shared Dispositive Power
 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 2,397,711.00
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 5.4 %

Type of Reporting Person (See Instructions)

12 IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Naegler, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Naegler, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares.

SCHEDULE 13G

Item 1.

Name of issuer:

- (a) Quince Therapeutics, Inc.

Address of issuer's principal executive offices:

- (b) 611 Gateway Boulevard, Suite 273 South San Francisco, CA, 94080

Item 2.

Name of person filing:

- (a) The persons and entities filing this Schedule 13G are Sofinnova Capital VIII ("SC VIII"), Sofinnova Partners SAS ("SP SAS"), and Antoine Papiernik ("Papiernik"), Henriette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou") and Karl Naegler ("Naegler"), the members of the investment committee of SC VIII (together with SC VIII and SP SAS, the "Filing Persons"). SP SAS is the management company of SC VIII.

Address or principal business office or, if none, residence:

- (b) The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France.

Citizenship:

- (c) SC VIII is a French Partnership. SP SAS is a French Corporation. Papiernik is a French citizen. Richter is a Danish citizen. Bhaman is a British citizen. Seghezzi is an Italian citizen. Gkelou is a Greek citizen. Naegler is a German citizen.

Title of class of securities:

- (d) Common Stock, par value \$0.001 per share

CUSIP No.:

- (e) 22053A107

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Investment adviser

Item 4. Ownership

- (a) Amount beneficially owned:

See Row 9 of the cover page for each of the Filing Persons. The filing of this Schedule 13G shall not be construed as an admission by Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler that such person is, for the purposes of

Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement.

Percent of class:

(b) See Row 11 of the cover page for each of the Filing Persons. Ownership is stated as of December 31, 2024 and the ownership percentages are based on 44,001,643 shares outstanding as of November 5, 2024, as disclosed by Quince Therapeutics, Inc. in its Quarterly Report on Form 10-Q filed with the SEC on November 13, 2024. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row 5 of the cover page for each of the Filing Persons.

(ii) Shared power to vote or to direct the vote:

See Row 6 of the cover page for each of the Filing Persons.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of the cover page for each of the Filing Persons.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of the cover page for each of the Filing Persons.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Advisers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sofinnova Capital VIII

Signature: Antoine Papiernik

Name/Title: Managing Partner

Date: 02/14/2025

Sofinnova Partners SAS, a French corporation

Signature: Antoine Papiernik

Name/Title: Managing Partner

Date: 02/14/2025

Antoine Papiernik

Signature: Antoine Papiernik
Name/Title: Antoine Papiernik
Date: 02/14/2025

Henriette Richter

Signature: Henriette Richter
Name/Title: Henriette Richter
Date: 02/14/2025

Maina Bhaman

Signature: Maina Bhaman
Name/Title: Maina Bhaman
Date: 02/14/2025

Graziano Seghezzi

Signature: Graziano Seghezzi
Name/Title: Graziano Seghezzi
Date: 02/14/2025

Anta Gkelou

Signature: Anta Gkelou
Name/Title: Anta Gkelou
Date: 02/14/2025

Karl Naegler

Signature: Karl Naegler
Name/Title: Karl Naegler
Date: 02/14/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

Joint Filing Agreement

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Quince Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to this agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf on February 14, 2025.

SOFINNOVA CAPITAL VIII
By: Sofinnova Partners SAS

SOFINNOVA PARTNERS SAS

By: /s/ Antoine Papiernik
Name: Antoine Papiernik
Title: Managing Partner

By: /s/ Antoine Papiernik
Name: Antoine Papiernik
Title: Managing Partner

By: /s/ Antoine Papiernik
Name: Antoine Papiernik

By: /s/ Henriette Richter
Name: Henriette Richter

By: /s/ Maina Bhaman
Name: Maina Bhaman

By: /s/ Graziano Seghezzi
Name: Graziano Seghezzi

By: /s/ Anta Gkelou
Name: Anta Gkelou

By: /s/ Karl Naegler
Name: Karl Naegler